Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Abatacept Injection

Supplied as a weekly injection via a pre-filled syringe

OTHER

Usual Care

Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs

Trial Locations (19)

10461

Children's Hospital at Montefiore/ Albert Einstein University Hospital, The Bronx

19104

Children's Hospital of Philadelphia, Philadelphia

27514

University of North Carolina, Chapel Hill

32610

Shands at the University of Florida, Gainesville

37232

Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville

40202

University of Louisville School of Medicine/ Norton Charities Pediatric Clinical Research Unit, Louisville

43205

Nationwide Children's Hospital, Columbus

44109

MetroHealth System, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

52242

University of Iowa Hospitals of Clinics, Iowa City

55454

University of Minnesota; Children's Hospital and Clinics of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

80045

The Children's Hospital Colorado, Aurora

84158

University of Utah, Salt Lake City

94143

University of California at San Francisco Medical Center, San Francisco

98105

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER

NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) | Biotech Hunter | Biotech Hunter